






























































The recent worldwide epidemic confirmed mater-nal–fetal transmission of Zika virus (ZIKV) and its 
association with adverse perinatal outcomes, particu-
larly severe central nervous system lesions and fetal 
losses (1–3). Whether prolonged viremia after ZIKV 
infection in pregnant women represents a risk factor 
for maternal–fetal transmission, congenital Zika syn-
drome (CZS), or other adverse outcomes is on ongo-
ing controversy (4).
ZIKV is detectable in maternal blood by reverse 
transcription PCR (RT-PCR) during the acute phase 
of infection. ZIKV viremia usually lasts from 2 days 
before to 16 days after symptom onset; median time 
of ZIKV RNA clearance is 5 days (5). Driggers et al. 
(6) detected ZIKV RNA in maternal serum samples 
8 weeks after onset of clinical symptoms; they sug-
gested that prolonged viremia might occur as a con-
sequence of viral replication in the fetus or placenta 
and might be correlated with CZS. In other reports, 
however, prolonged maternal viremia has been de-
scribed in pregnant women with both normal and 
adverse fetal outcomes (6–10).
In a cohort of pregnant women exposed to ZIKV 
in French Guiana, we investigated the impact of pro-
longed viremia on fetal and neonatal adverse out-
comes (fetal loss or neurologic anomalies) compared 
with infected pregnant women without prolonged 
viremia and noninfected pregnant women. We also 
compared the rates of congenital infections between 
these groups.
Methods
Study Population, Recruitment, and Follow-up
The study was conducted at the Centre Hospitalier de 
l’Ouest Guyanais (CHOG; Saint-Laurent-du-Maroni, 
in French Guiana) during January 1–July 15, 2016, 
at the beginning of the ZIKV epidemic. Persons for 
inclusion were initially identified either through rou-
tine serologic testing of all pregnant women admitted 
to the prenatal diagnosis unit of CHOG (performed in 
each trimester of pregnancy and at birth), or through 
serologic and molecular testing in cases of maternal 
symptoms, acute exposure in the previous 2 weeks 
(patients who arrived in French Guiana from a non-
endemic country or patients who arrived from an 
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Whether prolonged maternal viremia after Zika virus in-
fection represents a risk factor for maternal–fetal trans-
mission and subsequent adverse outcomes remains un-
clear. In this prospective cohort study in French Guiana, 
we enrolled Zika virus–infected pregnant women with a 
positive PCR result at inclusion and noninfected preg-
nant women; both groups underwent serologic testing 
in each trimester and at delivery during January–July 
2016. Prolonged viremia was defined as ongoing virus 
detection >30 days postinfection. Adverse outcomes (fe-
tal loss or neurologic anomalies) were more common in 
fetuses and neonates from mothers with prolonged vire-
mia (40.0%) compared with those from infected mothers 
without prolonged viremia (5.3%, adjusted relative risk 
[aRR] 7.2 [95% CI 0.9–57.6]) or those from noninfected 
mothers (6.6%, aRR 6.7 [95% CI 3.0–15.1]). Congenital 
infections were confirmed more often in fetuses and ne-
onates from mothers with prolonged viremia compared 
with the other 2 groups (60.0% vs. 26.3% vs. 0.0%, aRR 
2.3 [95% CI 0.9–5.5]).
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endemic country [e.g., Brazil in January 2016] before 
the epidemic began in French Guiana), fetal or neo-
natal central nervous system anomalies, or in cases of 
amniocentesis performed for suspected CZS or other 
indications (i.e., aneuploidy diagnosis). All pregnant 
women with ZIKV testing available with ongoing 
follow-up at CHOG were invited to participate in the 
study. Written consent was obtained from all partici-
pants. The study received ethics approval from the 
CHOG institutional review board (11). Data regard-
ing demographic, medical, and obstetrical character-
istics and possible risk factors for congenital diseases 
were collected prospectively at inclusion.
Patients were monitored in accordance with the 
clinical standard of care in France, with the exception 
that prenatal ultrasound was performed monthly for 
patients who tested positive for ZIKV. Two supple-
mentary ultrasounds were provided to patients who 
tested negative for ZIKV (at 26–28 and 36–38 weeks’ 
gestation), as recommended by health authorities in 
France and other organizations (12–15). In cases of 
fetal loss (>14 weeks’ gestation) or termination of 
pregnancy, a postmortem examination was offered, 
including macroscopic imaging and anatomic–patho-
logic examination.
In cases of live birth, a clinical examination (with 
particular attention to neurologic and systemic symp-
toms such as hypertonia, swallowing disorders, hy-
potonia, hepatomegaly, and jaundice) and testing 
for congenital ZIKV infection were performed for all 
neonates. Biologic, ophthalmologic, and imaging fol-
low-up was offered for neonates from ZIKV-infected 
pregnant women (16).
Pregnant women not followed at the CHOG pre-
natal diagnosis unit after ZIKV testing, as well as pa-
tients who only delivered at CHOG without appro-
priate prenatal follow-up, were excluded from this 
study. Fetuses or neonates who did not undergo test-
ing for ZIKV at birth or an appropriate postnatal or 
postmortem examination also were excluded.
Definition of Maternal ZIKV Infection
Molecular and serologic testing was performed at the 
French Guiana National Reference Center for arbo-
viruses (Institut Pasteur of French Guiana, Cayenne, 
French Guiana) using the Realstar Zika Kit (Altona 
Diagnostics GmbH, https://altona-diagnostics.com) 
for RT-PCR, in-house IgM and IgG antibody-capture 
ELISA, and microneutralization assays for serologic 
testing. The limit of detection for serum samples test-
ed using the Realstar Zika Kit was 0.61 (95% CI 0.39–
1.27) copies/µL  (17). A cycle threshold (Ct) value <37 
was considered positive.
When ZIKV RNA was initially detected, molecular 
diagnosis was performed monthly and at delivery on 
maternal serum samples. Prolonged viremia was de-
fined as ongoing viral detection >30 days after symptom 
onset or after initial detection of viremia in asymptom-
atic patients. Absence of prolonged viremia in infected 
patients was defined as a subsequent negative molecu-
lar test <30 days after symptom onset or after initial de-
tection of viremia in asymptomatic patients.
In all cases, ZIKV serologic tests were performed 
in each trimester of pregnancy and at delivery. Pa-
tients with only positive IgM without RT-PCR testing 
or with a negative RT-PCR result were excluded from 
the analysis.
Maternal symptoms potentially related to ZIKV 
were recorded at each prenatal visit and at birth. 
These symptoms included rash, fever, asthenia, pru-
ritus, arthralgia, retro-orbital headache, myalgia, 
conjunctival hyperemia, edema of the extremities, 
and neurologic complications (18). Asymptomatic 
pregnant women who remained ZIKV-negative on 
serologic tests during their pregnancy and at delivery 
were considered noninfected.
Definition of Fetal and Neonatal Adverse  
Outcomes and Congenital Infection 
Fetal and neonatal outcomes were reviewed by 3 
independent reviewers, including 2 maternal–fetal 
medicine specialists who had not been in contact with 
these patients previously. Cerebral anomalies were 
defined as >1 major cerebral sign, based on an ex-
tended definition of CZS (14,19,20) (Appendix 1 Table 
1, https://wwwnc.cdc.gov/EID/article/27/2/20-
0684-App1.pdf). Fetal loss was defined as a sponta-
neous fetal demise at >14 weeks’ gestation, including 
late miscarriages (14–24 weeks’ gestation) and still-
births (fetal demise >24 weeks’ gestation up to intra-
partum); intrapartum and early postpartum deaths 
were excluded. For the analysis, fetuses and neonates 
who had major cerebral anomalies, fetal losses, or 
both were categorized as having adverse outcomes. 
Termination of pregnancy for reasons other than ma-
jor cerebral abnormalities were not considered as ad-
verse outcomes in this analysis. 
All fetuses and neonates underwent ZIKV testing 
at birth or after fetal loss. Prenatal testing by amnio-
centesis was offered in those with fetal anomalies, if an 
amniocentesis was indicated for other indications (i.e., 
aneuploidy diagnosis), or both. A confirmed congeni-
tal ZIKV infection was defined either by ZIKV RNA 
amplification by RT-PCR from >1 fetal or neonatal 
sample (e.g., placenta, amniotic fluid, cerebrospinal 
fluid, urine, or blood) or identification of ZIKV-specific 
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IgM in the umbilical cord or neonatal blood or in cere-
brospinal fluid. Details of congenital ZIKV testing are 
discussed elsewhere (19).
Statistical Analyses
Standardized differences were calculated to compare 
baseline characteristics of patients with prolonged vi-
remia to those of the reference groups (i.e., pregnant 
women with positive RT-PCR results without pro-
longed viremia and noninfected pregnant women). 
These characteristics were considered unbalanced 
when the standardized difference was >0.15.
Relative risks (RRs) and 95% CIs were calculated 
for fetal and neonatal adverse outcomes by using gen-
eralized linear regression. Adjusted RRs (aRRs) were 
calculated for variables reflecting unbalanced baseline 
characteristics that could represent confounding factors 
(maternal age and maternal underlying conditions). 
When fetuses from mothers with prolonged viremia 
were compared with those from infected mothers 
without prolonged viremia, RRs were also adjusted for 
the trimester of maternal infection diagnosis. A robust 
SE option was used for twins in order to not affect the 
variance in considering twins as separate cases.
We conducted a sensitivity analysis to test the 
robustness of our findings, using different criteria 
for the diagnosis of maternal prolonged viremia. We 
compared fetuses and neonates from patients with 
stable or increasing quantitative PCR (qPCR) values 
between the inclusion and the first follow-up with 
those from mothers with decreasing qPCR values.
The missing data were considered to be random, 
and thus we performed a complete case analysis. All 
statistical analyses were conducted by using Stata 15 
(StataCorp, https://www.stata.com).
Results
Recruitment and Maternal ZIKV Diagnosis
During January 1–July 15, 2016, a total of 1,690 preg-
nant women were admitted to CHOG and tested for 
ZIKV infection (Figure 1). Among 498 women with a 
positive test, 198 were not prospectively followed in 
the CHOG prenatal diagnosis unit (including 20 pa-
tients with early miscarriages, 70 who were followed 
elsewhere after initial diagnosis of ZIKV infection, and 
108 with a diagnosis at delivery without appropriate 
prenatal follow-up). A total of 300 pregnant women 
(including 5 with dichorionic twin pregnancies) with 
a positive ZIKV test were monitored in the unit. Full 
fetal and neonatal testing and follow-up was avail-
able for 287 of them (including 4 with twin pregnan-
cies). Among these 287 ZIKV-positive patients, 254 
(including 3 with twin pregnancies) had ZIKV infec-
tion diagnosed only by positive IgM, without molecu-
lar testing or with negative molecular testing, prevent-
ing calculation of the start of viremia. These patients 
were excluded from the analysis. Positive molecular 
testing was found in 33 patients (including 1 with a 
twin pregnancy); 30 were positive by RT-PCR in mater-
nal blood, 9 were positive by RT-PCR in urine samples. 
Among these ZIKV RNA–positive pregnant women, 
14 (including 1 with a twin pregnancy) exhibited a 
prolonged viremia, whereas the other 19 became sub-
sequently negative within 30 days. Details of positive 
molecular testing are presented in Appendix 1 Table 
2 and the evolution of qPCR values for each positive 
patient in Appendix 2 Figure (https://wwwnc.cdc.
gov/EID/article/27/2/20-0684-App2.xlsx).
During the same period, 399 pregnant women (in-
cluding 6 with dichorionic twin pregnancies) with neg-
ative serologic test results for ZIKV were followed for 
routine scans at CHOG. Full maternal, placental, and 
neonatal testing was available for 326 of them (includ-
ing 6 with twin pregnancies). These patients remained 
negative for ZIKV during the entire pregnancy and at 
delivery, and constituted the noninfected group. The 
recruitment process is summarized in Figure 1.
Baseline Characteristics of Participants
As shown in Appendix 1 Table 3, baseline characteris-
tics were similar between pregnant women with pro-
longed viremia and the reference groups, except for 
a history of congenital abnormalities or intrauterine 
fetal demise, maternal underlying conditions, rate of 
dichorionic twins, and high risk for fetal aneuploidy 
(>1/250), for which standardized differences >0.15 
were observed. Maternal ZIKV infections were diag-
nosed earlier in pregnancies with prolonged viremia 
than in those without prolonged viremia.
Fetal and Neonatal Adverse Outcomes and  
Congenital Infections
ZIKV testing and outcomes were available for 15 
fetuses from 14 infected pregnant women with pro-
longed viremia (including 1 with a dichorionic twin 
pregnancy) (Appendix 1 Tables 4, 5). Two pregnan-
cies (2/15 [13.3%]) were terminated for severe neu-
rologic anomalies, and 2 fetal losses (2/15 [13.3%]) 
were recorded. Among fetuses with imaging studies 
and examinations available, 4 (4/14 [28.6%]) exhib-
ited neurologic anomalies and 4 (4/11 [36.4%]) ocu-
lar anomalies (Appendix 1 Table 4). Congenital ZIKV 
infections were confirmed in 9 (9/15 [60.0%]) of these 
fetuses or newborns, of which 6 (6/9 [66.7%]) cases 
resulted in adverse outcomes (4 suspected CZS and 2 
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fetal losses). All pregnancy outcomes for women with 
prolonged viremia are detailed in Figure 2. Figure 3 
presents an example of CZS related to maternal pro-
longed viremia.
Among 19 fetuses from mothers with an initially 
positive RT-PCR result without prolonged viremia, no 
fetal loss or termination of pregnancy was recorded. 
Neurologic anomalies were found in 1 (1/19 [5.3%]) of 
these fetuses, who also had ocular anomalies (confirmed 
at birth). Congenital ZIKV infections were confirmed 
in 5 (5/19 [26.3%]) of these newborns, of which 1 (1/5 
[20%]) resulted in adverse outcomes (suspected CZS).
ZIKV testing and outcomes were available for 332 
fetuses or newborns from noninfected pregnant wom-
en (including 6 with dichorionic twin pregnancies). 
Four pregnancies (4/332 [1.2%]) resulted in termina-
tion of pregnancy (1 for severe neurologic anomalies 
and 3 for extraneurologic anomalies [congenital heart 
disease, skeletal dysplasia, and Down syndrome]). 
Four (4/332 [1.2%]) fetal losses were recorded. Among 
the fetuses with imaging studies and examination 
available, 17 (17/331 [5.1%]) had neurologic anoma-
lies. None of these fetuses or neonates were found to 
be ZIKV-positive at birth.
Associations between Prolonged Viremia,  
Fetal and Neonatal Adverse Outcomes, and  
Congenital Infections
Overall, fetuses or neonates from mothers with a pro-
longed viremia during pregnancy exhibited a higher 
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Figure 1. Flowchart of pregnant women admitted to CHOG, French Guiana, January 1–July 15, 2016. All women were routinely tested 
for ZIKV-specific IgM and IgG in each trimester of pregnancy and at delivery. In cases of maternal symptoms, acute exposure in the 
previous 2 weeks, fetal anomalies, or if an amniocentesis was indicated, pregnant women were also tested for ZIKV RNA by RT-PCR 
in blood and urine. Patients with a positive RT-PCR result were offered to participate in the study and underwent monthly RT-PCR 
testing up to clearance or delivery. Prolonged viremia was defined as ongoing viral detection >30 days after symptom onset or after 
initial detection of viremia. Asymptomatic patients who remained negative for ZIKV IgM during the whole pregnancy were recruited and 
considered as non–ZIKV-infected. Patients with only positive IgM without or with a negative RT-PCR test result were excluded of this 
analysis because of the inability to accurately date the onset and clearance of viremia. Patients without appropriate monthly follow-up 
were also excluded from this study (e.g., those who had early miscarriages, late diagnosis of infection at delivery, or were not followed 
in our center after the diagnosis). After expulsion, fetal losses were tested by RT-PCR (as well as by IgM, if available). Fetuses with 
anomalies were tested by RT-PCR on amniotic fluid. Neonates were tested for ZIKV at birth (RT-PCR on placenta, urine, blood and 
IgM on blood [as well as on cerebrospinal fluid, if symptomatic]). Fetuses and neonates without appropriate testing and examination 
after fetal loss or birth were excluded from this analysis. Overall, 15 fetuses from 14 infected pregnant women with prolonged viremia 
(including 1 with a twin pregnancy), 19 fetuses from 19 infected pregnant women without prolonged viremia, and 332 fetuses from 326 
noninfected pregnant women (including 6 with twin pregnancies) were included. CHOG, Centre Hospitalier de l’Ouest Guyanais (Saint-
Laurent-du-Maroni, French Guiana); RT-PCR, reverse transcription PCR; ZIKV, Zika virus.
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risk for adverse outcomes (6/15 [40%] with fetal loss, 
neurologic anomalies, or both) compared with those 
from infected mothers without prolonged viremia 
(1/19 [5.3%], RR 7.6 [95% CI 1.0–56.5]) and noninfect-
ed mothers (20/332 [6.0%], RR 6.6 [95% CI 3.1–14.1]). 
Similar results were observed for fetal losses and 
neurologic anomalies when analyzed independently 
(Appendix 1 Table 4). After adjustment for maternal 
underlying conditions and considering the twin preg-
nancies in the variance, these associations and trends 
persisted (aRR 7.2 [95% CI 0.9–57.6] when compared 
with fetuses from infected mothers without prolonged 
viremia and aRR 6.7 [95% CI 3.0–15.1] when compared 
with fetuses from noninfected mothers). In the com-
parison with fetuses from infected mothers without 
prolonged viremia, the analysis was also adjusted for 
the trimester of maternal infection diagnosis (Appen-
dix 1 Tables 4, 6).
Congenital infections were confirmed more 
frequently in fetuses from mothers with prolonged 
viremia (9/15 [60.0%]) when compared with those 
from infected mothers without prolonged viremia 
(5/19 [26.3%], RR 2.3 [95% CI 1.0–5.4]) and nonin-
fected mothers (0/332 [0.0%]). After adjustment for 
the trimester of maternal infection diagnosis and 
consideration of twin pregnancies in the variance, 
this trend persists (aRR 2.3 [95% CI 0.9–5.5]) (Ap-
pendix 1 Tables 4, 6).
Our sensitivity analysis found similar results 
when considering the evolution of qPCR values be-
tween the inclusion and the first follow-up instead of 
prolonged viremia as a binary variable (Appendix 1 
Table 7). Neurologic or systemic symptoms at birth 
were also more frequent in newborns from mothers 
with prolonged viremia compared with those from 
infected mothers without prolonged viremia or non-
infected mothers (Appendix 1 Table 5).
Discussion
The main findings of this cohort study are 2-fold. First, 
maternal ZIKV infection with prolonged viremia is as-
sociated with a 7-fold increased risk for fetal or neonatal 
adverse outcomes compared with pregnancies with-
out prolonged viremia. Second, maternal prolonged 
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Figure 2. Pregnancy outcomes of patients with prolonged viremia in a cohort study of pregnant women admitted to Centre Hospitalier 
de l’Ouest Guyanais, French Guiana, January 1–July 15, 2016. Description and outcomes of 14 pregnancies with prolonged maternal 
ZIKV viremia (including 1 with dichorionic twin pregnancy). Congenital ZIKV infection was confirmed in 9/15 (60%) fetuses, and 6/15 
(40%) fetuses had adverse outcomes. Four of them had multiple abnormalities consistent with CZS (1 live birth, 1 TOP, 1 IUFD, and 1 
stillbirth). The 2 fetuses from the dichorionic twin pregnancy also had adverse outcomes, with an IUFD at 24 wk and a TOP for severe 
ventriculomegaly in the other fetus at 29 wk. CSF, cerebrospinal fluid; CZS, congenital Zika syndrome; HC, head circumference; IUFD, 
intrauterine fetal demise; RT-PCR, reverse transcription PCR; TOP, termination of pregnancy; ZIKV, Zika virus.
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viremia is associated with a 2-fold increased risk for 
confirmed congenital infection compared with infect-
ed mothers without prolonged viremia.
Our study was limited by the sample size of the 
infected group because only patients with a positive 
ZIKV RT-PCR result at enrollment were included in 
the analysis and followed up with monthly RT-PCR 
testing until clearance or delivery. Because the mea-
sured effect size was high, the sample size was suf-
ficient to identify an association. The limited number 
of cases with prolonged viremia, however, forced us 
to group all adverse outcomes together to conduct 
an analysis with sufficient power and prevented the 
evaluation of its association with individual signs or 
symptoms or new characteristics (21,22).
Although ZIKV testing was based on the previous 
guidelines relevant during the 2015–2016 epidemic 
with adaptation to local capacities, testing does not 
follow the more recent CDC guidelines (23) (i.e., pa-
tients considered as noninfected underwent serologic 
testing in each trimester rather than nucleic acid test-
ing, as is currently recommended). Patients included 
as noninfected, however, remained negative for IgM 
and IgG in each trimester and at delivery, limiting the 
risk for exposure misclassification. Similarly, women 
with only positive IgM testing were excluded from 
the study because some of them might have had un-
detected prolonged viremia, which would have led to 
an exposure misclassification and an underestimation 
of the consequences of prolonged viremia.
Information about the sensitivity and specific-
ity of neonatal testing remains limited, and several 
studies have shown the progressive disappearance of 
ZIKV RNA in the maternal–fetal compartments (24). 
Although the identification of IgM in fetal or neonatal 
blood was used to avoid congenital ZIKV false nega-
tives, we cannot exclude an outcome misclassification 
because some neonates with negative results could 
have been infected by ZIKV without viremia and im-
munity against ZIKV detectable at birth. This risk is 
likely low given that >80% of fetuses or neonates from 
infected pregnant women underwent testing in >3 
different samples (including blood, urine, placenta, 
cerebrospinal, and amniotic fluid) (19), and all neo-
nates from noninfected pregnant women underwent 
serologic testing at birth. Undetected congenital infec-
tions in the 2 reference groups might result in over-
estimation of the effect of prolonged viremia overall.
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Figure 3. Prenatal ultrasound, computed tomography, and postmortem aspect of a fetus with congenital Zika syndrome related to 
maternal prolonged viremia in patient (case no. 122) in a cohort study of pregnant women admitted to Centre Hospitalier de l’Ouest 
Guyanais, French Guiana, January 1–July 15, 2016. The mother had symptomatic acute Zika virus infection at 8 weeks’ gestation (and 
had ongoing viremia until birth of her stillborn child with signs of congenital Zika syndrome. Severe microcephaly, ventriculomegaly, and 
calcifications were detected by ultrasound at 13 weeks’ gestation. Overall, this fetus had arthrogryposis detected on 3-D ultrasound 
(A) and postmortem (B); severe bilateral microphthalmia (blue arrows) detected on 3-D ultrasound (C) and fetal computed tomography 
(D); microcephaly with atrophic cortex detected on ultrasound (E) showing a head circumference of 160 mm at 25 weeks’ gestation 
(−5 SDs); ventriculomegaly detected on ultrasound (E); brain calcifications (blue arrows) detected on ultrasound (F) and computed 
tomography (G); pontocerebellar hypoplasia (yellow arrows) detected on ultrasound (F); and corpus callosum dysgenesis (yellow 
arrows) detected on ultrasound (H).
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Neonates from noninfected mothers underwent 
postnatal transfontanellar ultrasound (as well as by 
computed tomography and magnetic resonance im-
aging, if available) only in the case of an abnormal 
prenatal ultrasound or symptoms at birth, in contrast 
to those from infected mothers who underwent rou-
tine postnatal imaging. However, when they are as-
ymptomatic, some neonates from noninfected moth-
ers might have undetected cerebral anomalies at birth, 
resulting in an overestimation of the consequences of 
prolonged Zika viremia. We cannot totally exclude 
this bias; however, all neonates from noninfected 
mothers underwent multiple prenatal ultrasound 
assessments (enhanced by 2 supplementary exami-
nations with neurosonograms during the epidemic), 
reducing the risk for undetected cerebral anomalies.
Molecular testing has been proposed for use 
at different stages of pregnancy depending on the 
presence of maternal symptoms. Thus, symptom-
atic patients might have had ZIKV infection diag-
nosed earlier than asymptomatic patients for whom 
a molecular diagnosis was proposed in cases of fetal 
anomalies, amniocentesis (for fetal signs or other 
indications [i.e., aneuploidy diagnosis]), or both, 
occurring later in pregnancy. Among infected preg-
nant women without prolonged viremia, 7 were 
asymptomatic with a continuous exposure and did 
not have molecular testing before amniocentesis, 
preventing accurate identification of the time of in-
fection during pregnancy. Thus, we cannot exclude 
that some of these patients were in fact infected ear-
lier in pregnancy and had an undetected prolonged 
viremia resulting in an exposure misclassification. 
This bias would result in an underestimation of the 
consequences of prolonged viremia because a case 
that included neurologic anomalies (CZS) in the 
reference group from infected mothers without pro-
longed viremia could in fact be related to prolonged 
viremia. Similarly, we cannot exclude a potential se-
lection bias given that some patients were tested by 
RT-PCR because their fetus had anomalies at inclu-
sion. Because this proportion did not differ between 
the groups (3/14 vs. 4/19), even if we consider only 
anomalies suggestive of fetal infection at inclusion 
(2/14 vs. 2/19), we would not expect relative risks to 
be significantly affected. However, this potential se-
lection bias could overestimate absolute frequencies 
of fetal anomalies in RT-PCR–positive patients, and 
this bias seems to be inherent in contemporary co-
horts because inclusion after the observation of fetal 
anomalies potentially related to Zika were common.
Driggers et al. (6) were the first to highlight a 
possible association between prolonged maternal 
viremia and congenital infection with CZS. In their 
cohort study, Rodo et al. (25) described 9 cases of 
prolonged maternal viremia, among which 2 result-
ed in congenital ZIKV infection, with 1 of those 2 
infections resulting in severe neurologic anomalies. 
The rates of congenital infection and fetal or neo-
natal adverse outcomes in women with prolonged 
viremia seem to be higher in our study (9/15 for 
congenital infections and 4/15 for CZS). This dif-
ference might be explained by the exclusive use of 
amniocentesis for diagnosis in the Rodo et al. cohort, 
whereas multiple fetal or neonatal samples were 
tested in our study (>80% of the fetuses or newborns 
had >3 different samples tested). Our results are 
congruent with Meaney et al. (10), who identified 
prolonged ZIKV RNA detection in 4 symptomatic 
pregnant women in the US Zika Pregnancy Registry, 
of which 1 pregnancy (25%) resulted in congenital 
Zika syndrome. Suy et al. (8) described a case of CZS 
with prolonged maternal viremia where the viral 
load in the maternal serum sample remained stable 
for 14 weeks and then became negative, instead of 
decreasing progressively, as would be expected. Suy 
et al. suggested that the prolonged viremia that was 
detected in the mother could be the result of viral 
replication in the fetus or placenta, which thus might 
act as a reservoir. However, their study still lacks a 
consensual threshold to define prolonged viremia. 
In our study, we defined prolonged viremia as on-
going viral detection >30 days after symptom onset 
or after initial detection of viremia for a question of 
feasibility. Indeed, many of our patients were liv-
ing around the Maroni River, in isolated areas, and 
came monthly to CHOG for their clinical follow-up. 
In light of this geographic distance, we decided that 
monthly RT-PCR testing in case of initial detection 
of viremia was the most appropriate. In the context 
of a smaller area with local facilities, testing patients 
every 2 weeks to fulfill the threshold used in other 
studies might have been useful (10,25).
Negative and positive predictive values of pro-
longed maternal viremia for congenital infections and 
adverse outcomes related to ZIKV seem to be moder-
ate because fetal and neonatal adverse outcomes and 
congenital infections also occur in pregnant women 
without identified prolonged viremia. One explana-
tion could be that prolonged viremia might reflect 
viral replication in the placenta without further in-
volvement for the fetus (27). In addition, some of our 
cases with prolonged maternal viremia (6/15) did 
not exhibit congenital infections, suggesting that pro-
longed maternal viremia might also reflect persistent 
viral replication in other reservoirs than the fetus or 
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the placenta. The study of Rodo et al. (10) and the 
CDC report (25) also described fetuses without con-
genital infection or adverse outcomes from mothers 
with prolonged viremia (10,25).
Our results also indicate that noninfected wom-
en exhibited a 5.1% risk for fetal neurologic anoma-
lies and 1.2% risk for fetal losses (higher than the 
estimation of 3% risk for neurologic anomalies and 
0.5%–1.0% risk for fetal losses in developed coun-
tries), reflecting that other etiologies for adverse 
perinatal outcomes remain present even in the con-
text of a ZIKV epidemic (28), particularly in French 
Guiana, where pregnant women are exposed to 
lead poisoning, poverty, and higher risk for under-
lying conditions (29). To reduce the impact of these 
cofounding factors on our assessment of adverse 
neonatal outcomes related to prolonged ZIKV vire-
mia, we chose to adjust the RR estimates for unbal-
anced maternal underlying conditions that might 
have an effect on the exposure and on adverse 
perinatal outcomes.
In conclusion, prolonged maternal ZIKV viremia 
could be a marker for an increased risk for maternal–
fetal transmission and subsequent adverse perinatal 
outcomes. Even if prolonged maternal viremia is not 
consistently present in cases of congenital infection, it 
might reflect active viral replication in the fetal–pla-
cental compartment and should lead to an enhanced 
prenatal and neonatal follow-up.
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Appendix 2 Figure.  Evolution of qPCR values (cycle threshold) are presented, according to gestational 
age at sampling, for each patients. Left: patients with prolonged viremia (positive PCR >30 days after 
initial detection); Right: Zika-infected patients without prolonged viremia (positive PCR at inclusion, with 
negative PCR at the first follow-up <30 days after the inclusion). Prolonged maternal Zika viremia study, 
French Guiana, 2016–2017. 
